Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE

lirentelimab (AK002) - Allakos

https://www.eventscribe.net/2022/ACG-Posters/ajaxcalls/PosterInfo.asp?PosterID=515323

Evan Dellon, MD, MPH 1; Mirna Chehade, MD, MPH 2; Robert M. Genta, MD 3; David A. Leiman, MD 4; Kathryn A. Peterson, MD, MSCI 5; Jonathan Spergel, MD, PhD 6; Joshua Wechsler, MD, MS 7; Enoch Bortey, PhD 8; Alan T. Chang, BS 8; Ikuo Hirano, MD, PhD 9

Sep 4, 2022